Shots:

• The DBS system with the Vercise Cartesia Directional Lead is evaluated in INTREPID study which demonstrated that patients treated with the Vercise System resulted in 48% improvement in motor function as measured by UPDRS III scores for 2yrs.
• The ImageReady MRI labeling for the Vercise Gevia DBS system used in a full-body MRI of patients with the latest advances in DBS therapy including directional stimulation and a longer-lasting rechargeable battery and is available in EU since 2017        
• The Vercise Gevia with Cartesia Directional Lead targets electrical stimulation in the brain to provide symptom relief and control of unwanted side effects in patients with PD and has received FDA’s approval in Jan’2019 following the first-generation Vercise DBS System approval in Dec’2017

Click here to­ read full press release/ article | Ref: Boston Scientific | Image: Boston Scientific